RxDoctor Payments Data

Fernando Zamudio, MD

Cardiovascular Disease · San Diego, CANPI 1306842950

Payments from drug & device makers

$2,798in general payments, 2019–2025

Across 88 payments — averaging $31.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$710
  • AstraZeneca$360
  • Johnson & Johnson$272
  • Sanofi-aventis U.S. LLC$244
  • Boston Scientific$189
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$141
  • plus $882 from 13 others

What the payments were for

  • Food & beverage$2,798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,798 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$54,269
Medicare patients
145
Services billed
476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$66,576
XareltoRivaroxaban57$56,517
Potassium Chloride42$1,695
Telmisartan26$1,585
Metoprolol Succinate73$1,494
Rosuvastatin Calcium28$919
Valsartan27$853
ClopidogrelClopidogrel Bisulfate42$744
Atorvastatin Calcium57$690
Carvedilol55$641
Digoxin21$597
Amlodipine Besylate47$586
Fludrocortisone Acetate12$579
Nebivolol Hcl11$578
Losartan Potassium51$452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$115$66,57669 claims
Johnson & JohnsonXarelto$272$56,51757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →